Deucravacitinib demonstrates superior skin clearance in two Phase III psoriasis studies compared to apremilast

In the POETYK PSO-1 and POETYK PSO-2 studies, at week 16, 58.7% and 53.6% of patients receiving the selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, achieved Psoriasis Area and Severity Index (PASI) 75 response vs 35.1% and 40.2% receiving apremlilast, respectively.

Source:

PharmaTimes